Access to Technology Development Process
NCI investigators are provided access to the technologies developed within the ATP in four ways: 1) during the developmental phase as collaborators; 2) by transition of the technology to core services; 3) through publication of the method/application in a peer reviewed journal; and 4) through development of a commercial product stemming from the licensing of the technology to industry.
- Collaborative Development with NCI Scientists:
- Transition of Technologies to Core Services:
- Publication of Method/Application: Describe here.
- Commercial Interactions:
Recently the Antibody Characterization Laboratory (ACL) signed a Cooperative Research and Development Agreement with Epitomics Inc. to characterize monoclonal antibodies in the ACL’s assays. The Protein Chemistry Laboratory (PCL) is exploring new instrumentation for Fluorescence Correlation Spectroscopy (FCS) from Sensor Technologies LLC). This instrumentation measures the diffusion constants of molecular complexes at the single molecule level and hence their binding affinity.
